Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972993 · ClinicalTrials.gov registry record · Phase 1
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
A Phase 1 study of COVID-19, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
- 4
- Study locations
NCT05972993 is a Phase 1 study of COVID-19 that has completed, run by GlaxoSmithKline. The registered enrollment target is 114 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05972993, a Phase 1 study of COVID-19, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL mRNA-CR-04 vaccine 10μg
- BIOLOGICAL mRNA-CR-04 vaccine 30μg
- BIOLOGICAL mRNA-CR-04 vaccine 100μg
- BIOLOGICAL mRNA-CR-04 vaccine 3μg
Study Locations (4)
California
- GSK Investigational Site - San Diego
Florida
- GSK Investigational Site - Melbourne
Illinois
- GSK Investigational Site - Peoria
Texas
- GSK Investigational Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2023-08-07 |
| Est. Completion | 2024-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05972993
The ClinicalTrials.gov registry entry for NCT05972993 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT05972993 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05972993 about?
NCT05972993 is a clinical study titled "A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults". The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.
What is the current status of trial NCT05972993?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2023-08-07. Estimated completion is 2024-10-14.
What conditions does trial NCT05972993 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05972993?
The interventions under investigation include: Placebo (DRUG), mRNA-CR-04 vaccine 10μg (BIOLOGICAL), mRNA-CR-04 vaccine 30μg (BIOLOGICAL), mRNA-CR-04 vaccine 100μg (BIOLOGICAL), mRNA-CR-04 vaccine 3μg (BIOLOGICAL).
Who is sponsoring clinical trial NCT05972993?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05972993 being conducted?
This trial has 4 study locations across California, Florida, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
RECRUITING · Phase 1
-
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
ACTIVE NOT RECRUITING · Phase 1
-
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.